RT Book, Section
A1 Rohs, Nicholas
A1 Jackman, David M.
A1 Ciofreddi, Leigh-Anne
A1 Gomez, Jorge E.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Burt, Bryan M.
A2 Groth, Shawn S.
A2 Loor, Gabriel
A2 Wolf, Andrea S.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1170414043
T1 Systemic Chemotherapy for Mesothelioma
T2 Sugarbaker’s Adult Chest Surgery, 3e
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260026931
LK accesssurgery.mhmedical.com/content.aspx?aid=1170414043
RD 2023/10/04
AB Mesothelioma  is  a  rare,  aggressive  malignancy  arising  from  the  mesothelial  surfaces  of  the  pleura,  peritoneum,  pericardium,  or  tunica  vaginalis.  Incidence  of  the  disease  peaked  in  the  United  States  in  the  mid-1990s  with  approximately  2500  to  3000  new  cases  diagnosed  annually.  However,  its  incidence  in  many  other  parts  of  the  world,  particularly  in  rapidly  industrializing  regions  without  sufficient  asbestos  regulation,  will  continue  to  rise  over  the  next  few  decades.1  Despite  attempts  at  aggressive  multimodality  therapy  for  seemingly  localized  disease,  prognosis  for  mesothelioma  continues  to  be  dismal,  with  median  overall  survival  of  approximately  1  year.2  Since  its  updated  indication  in  2004,  pemetrexed  remains  the  only  chemotherapy  specifically  approved  by  the  U.S.  Food  and  Drug  Administration  (FDA)  for  the  treatment  of  mesothelioma.  Considering  the  high  rates  of  disease  recurrence  or  progression,  the  development  of  effective  systemic  treatment  options  for  mesothelioma  is  sorely  needed.